Compare VCEL & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | ATEC |
|---|---|---|
| Founded | 1989 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 1996 | 2006 |
| Metric | VCEL | ATEC |
|---|---|---|
| Price | $33.74 | $10.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $58.50 | $22.00 |
| AVG Volume (30 Days) | 718.0K | ★ 2.2M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | 15.04 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $276,259,000.00 | $101,739,000.00 |
| Revenue This Year | $19.10 | $18.97 |
| Revenue Next Year | $17.95 | $16.26 |
| P/E Ratio | $106.66 | ★ N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $28.95 | $8.82 |
| 52 Week High | $45.97 | $23.29 |
| Indicator | VCEL | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 31.47 |
| Support Level | $30.41 | $10.21 |
| Resistance Level | $34.34 | $11.43 |
| Average True Range (ATR) | 1.76 | 0.55 |
| MACD | 0.29 | -0.04 |
| Stochastic Oscillator | 83.11 | 8.91 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.